

CLAIMS

1. Use of an anti-CD70 antibody or antigen-binding fragment thereof for the manufacture of a medicament for treating acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) in a subject, wherein the subject is not eligible for standard intensive chemotherapy prior to treatment and/or wherein the subject is 60 years old or older.
2. Use of a combination comprising an anti-CD70 antibody or antigen binding fragment thereof and a NMI for the manufacture of a medicament for treating acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) in a subject, wherein the subject is not eligible for standard intensive chemotherapy prior to treatment and/or wherein the subject is 60 years old or older.
3. Use of a combination according to claim 2, wherein the NMI is a hypomethylating agent, optionally azacitidine.
4. Use of a combination according to claim 2 or claim 3, wherein the anti-CD70 antibody or antigen-binding fragment thereof inhibits CD70-CD27 binding and/or wherein the anti-CD70 antibody or antigen-binding fragment thereof depletes CD70-expressing cells.
5. Use of a combination according to any one of claims 2-4, wherein the anti-CD70 antibody comprises a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH and VL domains comprise the CDRs:

HCDR3 comprising or consisting of SEQ ID NO:3 (DAGYSNHVPIFDS)

HCDR2 comprising or consisting of SEQ ID NO:2 (DINNEGTTYYADSVKG)

HCDR1 comprising or consisting of SEQ ID NO:1 (VYYMN)

LCDR3 comprising or consisting of SEQ ID NO:7 (ALFISNPSVE)

LCDR2 comprising or consisting of SEQ ID NO:6 (NTNTRHS), and

LCDR1 comprising or consisting of SEQ ID NO:5 (GLKSGSVTSDNFPT).
6. Use of a combination according to claim 5, wherein the anti-CD70 antibody or antigen-binding fragment comprises a VH domain at least 80% identical to SEQ ID NO:4 and/or comprises a VL domain at least 80% identical to SEQ ID NO:8.
7. Use of a combination according to any one of claims 2-6, wherein the anti-CD70 antibody is an IgG1 antibody.
8. Use of a combination according to any one of claims 2-7, wherein the anti-CD70 antibody is ARGX-110.

9. Use of an anti-CD70 antibody or antigen binding fragment thereof in combination with a hypomethylating agent, preferably azacitidine for the manufacture of a medicament for the treatment of AML or MDS in a subject, wherein the subject is not eligible for standard intensive chemotherapy prior to treatment and/or wherein the subject is 60 years old or older.